confirmed what Tony is saying re: Autism. I also recall that comment in a webinar.
It was along the lines of the endpoints and success criteria for Autism would be too complex and cumbersome to pursue (at this stage). Benefit was instead best realised by targeting specific neurological disorders with unmet need (hence our current program for the 3-4 indications).
confirmed what Tony is saying re: Autism. I also recall that...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.65 |
Change
0.000(0.00%) |
Mkt cap ! $1.744B | |||
| Open | High | Low | Value | Volume |
| $13.70 | $13.76 | $13.56 | $3.689M | 270.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.66 | 1132 | 2 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |